Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapy-related myelodysplastic syndrome.

Expert opinion on drug safety - 1 May 2015

Candelaria Myrna, Dueñas-Gonzalez Alfonso

Abstract excerpt

INTRODUCTION: Myelodysplastic syndrome (MDS) is a heterogeneous clonal disorder characterized by deregulation of apoptosis, dysplastic features in hematopoietic precursors, peripheral blood cytopenias and an increased risk for transformation to acute leukemia. Roughly 20% of MDS are therapy related (t-MDS), and this is considered an independent adverse prognostic factor. AREAS COVERED: This review based on a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Genetic Predisposition to Disease
Share to Hematopoiesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hematopoietic Stem Cells

Share to Leukemia

Share to Myelodysplastic Syndromes

Share to Prognosis

Share to Risk Factors

Source

Identifiers

PMID: 25675961
DOI: 10.1517/14740338.2015.1014340

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapy-related myelodysplastic syndrome.PMID 25675961Read ↗

Therapy-related myelodysplasia and acute myeloid leukemia.Semantic proximity Read ↗

The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment.Semantic proximity Read ↗

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read ↗

Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions: Myelodysplastic Syndromes.Semantic proximity Read ↗

Treatment-related myelodysplastic syndrome: molecular characteristics and therapy.Semantic proximity Read ↗

Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the diseaseSemantic proximity Read ↗

Myelodysplastic SyndromesSemantic proximity Read ↗

Current therapeutic approaches for patients with myelodysplastic syndromes.Semantic proximity Read ↗

Therapy-Related Myeloid Neoplasm: Biology and Mechanistic Aspects of Malignant ProgressionSemantic proximity Read ↗

Myelodysplastic syndromes.Semantic proximity Read ↗

Myelodysplastic syndromes: molecular pathogenesis and genomic changes.Semantic proximity Read ↗

Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.